Principal Financial Group Inc. Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Principal Financial Group Inc. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 209,021 shares of the medical research company’s stock after purchasing an additional 1,750 shares during the quarter. Principal Financial Group Inc. owned approximately 0.12% of IQVIA worth $49,532,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Oddo BHF Asset Management Sas purchased a new position in shares of IQVIA during the third quarter worth approximately $2,771,000. Franklin Resources Inc. grew its holdings in shares of IQVIA by 1.2% during the 3rd quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock valued at $117,031,000 after purchasing an additional 6,011 shares during the last quarter. Tidal Investments LLC raised its position in IQVIA by 9.3% in the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock worth $1,417,000 after purchasing an additional 509 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in IQVIA during the third quarter valued at about $2,310,000. Finally, Arvest Bank Trust Division bought a new position in shares of IQVIA during the third quarter valued at about $21,079,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IQV shares. Morgan Stanley dropped their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Truist Financial cut their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Barclays lowered their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Finally, Stephens started coverage on shares of IQVIA in a research note on Friday. They set an “overweight” rating and a $250.00 price objective for the company. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Price Performance

Shares of IQV stock opened at $197.27 on Monday. The business’s fifty day moving average is $208.90 and its 200 day moving average is $223.32. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $35.80 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.05 and a beta of 1.49. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.